SCHEMBL211000

SCHEMBL211000

O=C(O)c1ccc(N2CC[C@@H](O)C2)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.63
WDR91 A4D1P6 3/20 0.52
KDM4E B2RXH2 1/20 0.51
NOTUM Q6P988 4/20 0.47
CASR P41180 3/20 0.46
AR P10275 1/20 0.46
ALDH1A1 P00352 1/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
ABL1 P00519 1/20 0.43
CHEK1 O14757 1/20 0.43
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
RORC P51449 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL211001 1.00 USP2 (0.63) USP2WDR91KDM4ENOTUMCASR
SCHEMBL25313533 1.00 USP2 (0.63) USP2WDR91KDM4ENOTUMCASR
SCHEMBL1663436 0.90 USP2 (0.55) USP2WDR91KDM4ENOTUMCASR
SCHEMBL1662934 0.89 USP2 (0.72) USP2WDR91KDM4EALDH1A1CA12
Hydrochloric Acid SCHEMBL5237325 0.88 USP2 (0.70) USP2WDR91KDM4ECASRALDH1A1
SCHEMBL14331837 0.85 USP2 (0.56) USP2KDM4EALDH1A1CA12CA1
SCHEMBL27918385 0.85 WDR91 (0.51) USP2WDR91NOTUMARABL1
SCHEMBL13837404 0.85 USP2 (0.61) USP2WDR91KDM4ENOTUMCASR
SCHEMBL13837407 0.85 USP2 (0.61) USP2WDR91KDM4ENOTUMCASR
SCHEMBL209690 0.81 USP2 (0.61) USP2KDM4ENOTUMCASRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK 2023-12-28 US disclosed
EP-4217355-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 Forkhead Biotherapeutics, inc. (US) 2023-08-02 EP disclosed
CN-110475775-B 4-pyridone compound or salt thereof, pharmaceutical composition containing 4-pyridone compound, and agent 富士胶片株式会社 2023-05-09 CN disclosed
WO-2022066938-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FORKHEAD BIOTHERAPEUTICS, INC. (US) 2022-03-31 WO disclosed
US-11161830-B2 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same FUJIFILM CORPORATION (JP) 2021-11-02 US disclosed
EP-3604301-B1 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME FUJIFILM CORP (JP) 2021-09-22 EP disclosed
EP-3604301-A1 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME FUJIFILM Corporation (JP) 2020-02-05 EP disclosed
EP-1735319-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2017-05-03 EP disclosed
CN-103282034-A Use of hematopoietic growth factor mimetics LIGAND PHARM INC 2013-09-04 CN disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FOXO1, FOXO3, GCKR USP2 2864/4885WDR91 1508/4885KDM4E 1362/4885
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 USP2 1509/4885WDR91 547/4885KDM4E 258/4885
US-11161830-B2 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same HAVCR2, HBS1L, PHKB USP2 4880/4885WDR91 1213/4885KDM4E 1384/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 USP2 1643/4885WDR91 705/4885KDM4E 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.